✦ LIBER ✦

Neoadjuvant therapy as a paradigm to develop systemic cancer therapy

✍ Scribed by Guru Sonpavde

Publisher: John Wiley and Sons
Year: 2008
Tongue: English
Weight: 112 KB
Volume: 69
Category: Article
ISSN: 0272-4391
DOI: 10.1002/ddr.20270

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Axillary staging prior to or after neoad

Axillary staging prior to or after neoadjuvant systemic therapy? A single institutional experience

✍ Fatema Al Mushawah; Marcus C. Tan; Julie A. Margenthaler 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 140 KB

Residual Nodal Disease in Biopsy Proven

Residual Nodal Disease in Biopsy Proven N1/N2 Breast Cancer Following Neoadjuvant Systemic Therapy

✍ Fatema Al Mushawah; Marcus C. Tan; Julie A. Margenthaler 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 154 KB

Response to neoadjuvant therapy with cis

Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients

✍ T. Byrski; T. Huzarski; R. Dent; J. Gronwald; D. Zuziak; C. Cybulski; J. Kladny; 📂 Article 📅 2008 🏛 Springer US 🌐 English ⚖ 149 KB

Laboratory models of breast and endometr

Laboratory models of breast and endometrial cancer to develop strategies for antiestrogen therapy

✍ Ruth M. O’Regan; Gale M. England; Jennifer I. MacGregor; Kathy A. Yao; Henry D. 📂 Article 📅 1998 🏛 Springer Japan 🌐 English ⚖ 966 KB

Screening for clonal hematopoiesis as a

Screening for clonal hematopoiesis as a predictive marker for development of therapy-related myeloid neoplasia (t-MN) following neoadjuvant therapy for breast cancer: a Southwest Oncology Group study (S0012)

✍ Marilyn L. Slovak; Victoria Bedell; Danika Lew; Kathy S. Albain; Georgiana K. El 📂 Article 📅 2009 🏛 Springer US 🌐 English ⚖ 322 KB

Neoadjuvant photodynamic therapy as a ne

Neoadjuvant photodynamic therapy as a new approach to treating hilar cholangiocarcinoma : A Phase II pilot study

✍ Marcus Wiedmann; Karel Caca; Frieder Berr; Ingolf Schiefke; Andrea Tannapfel; Ch 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 287 KB

## Abstract ## BACKGROUND Only 20–30% of patients with hilar cholangiocarcinomas (CC) are candidates for potentially curative resection. However, even after curative (R0) resection, these patients have a disease recurrence rate of up to 76%. The current prospective Phase II study investigated phot